The number of persons being vaccinated with influenza vaccines worldwide will touch the figure of 500 Million by the year-end of 2027
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccines, the introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most of the countries.
Long–term Growth Projection:
• The global influenza vaccines market size is set to surpass US$ 6.5 Billion by the year-end of 2021
• Influenza vaccines demand is expected to increase in the forecast period
• The United States influenza vaccines market is projected to grow with a significant CAGR in the forecast period
• In Japan, the influenza vaccines market holds a rewarding growth opportunity for the future as the demand for the vaccine isgrowing significantly
• The Chinese influenza vaccines market is expected to record a value of nearly US$ 180 Million by the year-end of 2027
• Europe is anticipated to be the fastest-growing market during the forecast period
• The United Kingdom and Germany are the leading revenue generators of the market
• Emerging players backed by technological advancements are developing vaccines that offer a more realistic experience
Key Features of the Study:
• The Market Size of the Global Influenza Vaccines Market with Six Years Forecast
• The Market Size of the Regional and National Influenza Vaccines Market with Six Years Forecast
• Scrutinizes the Global Overall Persons Being Vaccinated with Influenza Vaccines
• Scrutinizes the Regional and National Persons Being Vaccinated with Influenza Vaccines
• Delivers a Latest Happenings in the Global Influenza Vaccines Market
• Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan
• Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Distribution, Exclusive and Licensing Agreement
• Reviews Most Recent Clinical Trials of the Influenza Vaccines
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
The Report Analyses the Market Based on Countries and Presents the Forecast in Terms of Value and Volume for the Next Six Years. Twenty-One Major Markets (21MM) Covered in the Report are as follows:
1) United States
2) Canada
3) Brazil
4) Germany
5) France
6) Italy
7) Spain
8) United Kingdom
9) Netherlands
10) Sweden
11) Denmark
12) Poland
13) Norway
14) Finland
15) Ireland
16) Belgium
17) Australia
18) New Zealand
19) Japan
20) China
21) India
The Report Provides a Comprehensive Analysis of Company Profiles Listed Below:
• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus (CSL Limited)
• AstraZeneca
• Mylan
• BioDiem
• Novavax
• Medicago
• Moderna Inc
• Pneumagen
• Daiichi–Sankyo
• Altimmune
• FluGen
• Imutex
• EpiVax
• Versatope Therapeutics, Inc.
• Gamma Vaccines Pty Ltd.
• BiondVax Pharmaceuticals Ltd.
• Hualan Biological Engineering Inc.
• Shanghai Institute of Biological Products Co., Ltd.
The Report Answers Questions Such As:
• What is the current size of the global influenza vaccines market? How much will this market be worth from 2020 to 2027?
• How many persons being vaccinated with influenza vaccines globally during 2015 – 2027?
• Which country is expected to hold the highest market share in theglobal influenza vaccine market?
• What are the main drivers and restraints in the global influenza vaccines market?
• What are the major deals happenings in the global influenza vaccines market?
• Who are the top players and what are their activities, revenue, recent developments, and prospects?
• What are some of the most prominent influenza vaccines currently in development? What are their activities, phase, platform technology, and recent developments?
'
1. Executive Summary
2. Global Number of Persons Vaccinated with Influenza Vaccines and Forecast (2015 – 2027)
3. Global Influenza Vaccines Market Revenue and Forecast (2015 – 2027)
4. Global Influenza Vaccines Market Share and Y–o–Y Growth (%)
4.1 Number of Persons Vaccinated with Influenza Vaccines Share,2015 – 2027(%)
4.2 Influenza Vaccines Market Share,2015 - 2027(%)
5. Global Influenza Vaccines Market Drivers and Inhibitors
5.1 Market Drivers
5.2 Market Inhibitors
6. Global Influenza Vaccines Market, By Geography (Volume and Value),2015 – 2027
6.1 United States
6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.1.2 United States Influenza Vaccines Market Revenue (2015 – 2027)
6.2 Canada
6.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.2.2 Canada Influenza Vaccines Market Revenue (2015 – 2027)
6.3 Germany
6.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.3.2 Germany Influenza Vaccines Market Revenue (2015 – 2027)
6.4 France
6.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.4.2 France Influenza Vaccines Market Revenue (2015 – 2027)
6.5 Italy
6.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.5.2 Italy Influenza Vaccines Market Revenue (2015 – 2027)
6.6 Spain
6.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.6.2 Spain Influenza Vaccines Market Revenue (2015 – 2027)
6.7 United Kingdom
6.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.7.2 United Kingdom Influenza Vaccines Market Revenue (2015 – 2027)
6.8 Netherlands
6.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.8.2 Netherlands Influenza Vaccines Market Revenue (2015 – 2027)
6.9 Sweden
6.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.9.2 Sweden Influenza Vaccines Market Revenue (2015 – 2027)
6.10 Denmark
6.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.10.2 Denmark Influenza Vaccines Market Revenue (2015 – 2027)
6.11 Poland
6.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.11.2 Poland Influenza Vaccines Market Revenue (2015 – 2027)
6.12 Norway
6.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.12.2 Norway Influenza Vaccines Market Revenue (2015 – 2027)
6.13 Finland
6.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.13.2 Finland Influenza Vaccines Market Revenue (2015 – 2027)
6.14 Ireland
6.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.14.2 Ireland Influenza Vaccines Market Revenue (2015 – 2027)
6.15 Belgium
6.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.15.2 Belgium Influenza Vaccines Market Revenue (2015 – 2027)
6.16 Australia
6.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.16.2 Australia Influenza Vaccines Market Revenue (2015 – 2027)
6.17 New Zealand
6.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.17.2 New Zealand Influenza Vaccines Market Revenue (2015 – 2027)
6.18 Japan
6.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.18.2 Japan Influenza Vaccines Market Revenue (2015 – 2027)
6.19 Brazil
6.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.19.2 Brazil Influenza Vaccines Market Revenue (2015 – 2027)
6.20 China
6.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.20.2 China Influenza Vaccines Market Revenue (2015 – 2027)
6.21 India
6.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.21.2 India Influenza Vaccines Market Revenue (2015 – 2027)
6.22 Rest of the World (ROW)
6.22.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.22.2 ROW Influenza Vaccines Market Revenue (2015 – 2027)
7. Recent Development in the Global Influenza Vaccines Market
8. Global Influenza Vaccines Market – Regulatory System
8.1 United States
8.2 Europe
8.3 Japan
9. Major Deals in the Global Influenza Vaccines Market
9.1 Merger and Acquisitions
9.2 Collaboration Deals
9.3 Licensing Agreement
9.4 Exclusive Agreement
9.5 Distribution Agreement
10. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
10.1 Year 2020
10.2 Year 2019
11. Key Companies Analysis
11.1 Sanofi Pasteur
11.1.1 Business Overview
11.1.2 Influenza Vaccines Portfolio
11.1.3 Influenza Vaccines Value Sales Analysis
11.1.4 Promising Influenza Vaccines in the Clinical Development
11.1.5 Recent Development
11.2 GlaxoSmithKline (GSK)
11.2.1 Business Overview
11.2.2 Influenza Vaccines Portfolio
11.2.3 Influenza Vaccines Sales Value Analysis
11.2.4 Recent Development
11.3 Seqirus (CSL Limited)
11.3.1 Business Overview
11.3.2 Influenza Vaccines Portfolios
11.3.3 Influenza Vaccines Sales Value Analysis
11.3.4 Promising Influenza Vaccines in the Clinical Development
11.3.5 Recent Development
11.4 AstraZeneca
11.4.1 Business Overview
11.4.2 Influenza Vaccines Portfolio
11.4.3 Influenza Vaccines Sales Value Analysis
11.4.4 Recent Development
11.5 Gamma Vaccines Pty Ltd
11.5.1 Business Overview
11.5.2 Influenza Vaccines Portfolio
11.5.3 Recent Development
11.6 Hualan Biological Engineering Inc
11.6.1 Business Overview
11.6.2 Influenza Vaccines Portfolio
11.6.3 Recent Development
11.7 Shanghai Institute of Biological Products Co., Ltd.
11.7.1 Business Overview
11.7.2 Influenza Vaccine Portfolio
11.8 Mylan
11.8.1 Business Overview
11.8.2 Influenza Vaccine Portfolio
11.9 BioDiem
11.9.1 Business Overview
11.9.2 Influenza Vaccine Portfolio
11.9.3 Recent Development
12. Emerging Players
12.1 Novavax
12.1.1 Business Overview
12.1.2 Promising Influenza Vaccines in the Clinical Development
12.1.3 Recent Development
12.2 BiondVax Pharmaceuticals Ltd.
12.2.1 Business Overview
12.2.2 Promising Influenza Vaccines in the Clinical Development
12.2.3 Recent Development
12.3 Medicago
12.3.1 Business Overview
12.3.2 Promising Influenza Vaccines in the Clinical Development
12.3.3 Recent Development
12.4 Moderna Inc
12.4.1 Business Overview
12.4.2 Promising Influenza Vaccines in the Clinical Development
12.4.3 Recent Development
12.5 Pneumagen
12.5.1 Business Overview
12.5.2 Promising Influenza Vaccines in the Clinical Development
12.5.3 Recent Development
12.6 Altimmune
12.6.1 Business Overview
12.6.2 Promising Influenza Vaccines in the Clinical Development
12.6.3 Recent Development
12.7 Daiichi Sankyo
12.7.1 Business Overview
12.7.2 Promising Influenza Vaccines in the Clinical Development
12.7.3 Recent Development
12.8 FluGen
12.8.1 Business Overview
12.8.2 Promising Influenza Vaccines in the Clinical Development
12.8.3 Recent Development
12.9 Imutex
12.9.1 Business Overview
12.9.2 Promising Vaccines in the Clinical Development
12.9.3 Recent Development
12.10 EpiVax
12.10.1 Business Overview
12.10.2 Promising Influenza Vaccines in the Clinical Development
12.10.3 Recent Development
12.11 Versatope Therapeutics, Inc.
12.11.1 Business Overview
12.11.2 Promising Influenza Vaccines in the Clinical Development
12.11.3 Recent Development
List of Tables:
Table 4–1: Global Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2015 – 2020
Table 4–2: Global Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2021 – 2027
Table 4–3: Global Influenza Vaccines Market Share (Percent),2015 – 2020
Table 4–4: Global Influenza Vaccines Market Share Forecast (Percent),2021 – 2027
Table 8–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 9–2: Collaboration Deal in the Influenza Vaccines Market
Table 9–3: Licensing Agreement in the Influenza Vaccines Market
Table 9–4: Exclusive Agreement in the Influenza Vaccines Market
Table 9–5: Distribution Agreement in the Influenza Vaccines Market
Table 11–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 11–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 12–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 12–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 12–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 12–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 12–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 12–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 12–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 12–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 12–9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 12–10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 12–11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures:
Figure 2–1: Global Number of Persons Vaccinated with Influenza Vaccines (Thousand),2015 – 2020
Figure 2–2: Global Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2021 – 2027
Figure 3–1: Global Influenza Vaccines Market (Million US$),2015 – 2020
Figure 3–2: Global Influenza Vaccines Market Forecast (Million US$),2021 – 2027
Figure 6–1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–3: United States Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–7: Canada Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–11: Germany Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–15: France Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–16: France Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–19: Italy Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–23: Spain Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–31: Netherlands Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–35: Sweden Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–39: Denmark Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–43: Poland Influenza Vaccines Revenue Market (Million US$),2015 – 2020
Figure 6–44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–47: Norway Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–51: Finland Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–55: Ireland Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–59: Belgium Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–63: Australia Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–67: New Zealand Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–71: Japan Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–75: Brazil Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–79: China Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–80: China Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–83: India Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–84: India Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–85: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–86: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–87: ROW Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–88: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 11–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
Figure 11–3: GSK Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
Figure 11–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
Figure 11–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
